Available Online at http://www.recentscientificcom

CODEN: IJRSFP (USA)

International Journal of Recent Scientific Research
Vol. 15, Issue, 12, pp.5115-5127,December , 2024

International Journal of Recent Scientific Research

ISSN: 0976-3031

RESEARCH ARTICLE

PSYCHOBIOTICS: A PROMISING FRONTIER IN MENTAL HEALTH

VNR Sri Pranavi[1]., B.V. Vivekananda Reddy[2]., N. Jyothsna Reddy[3] and E. Naga Mallika[4]

[1]Final year MBBS Student, Gandhi Medical College, Telangana.
[2,4]Assistant Professor, Department of Livestock Products Technology,
Sri Venkateswara Venkateswara Veterinary University, Andhra Pradesh.
[3]Civil Assistant Surgeon, Community Health Centre, Mydukur, Andhra Pradesh.

DOI: http://dx.doi.org/10.24327/ijrsr.20241512.0965

ARTICLE INFO

Article History:

Received 1st November, 2024
Received in revised form 10th November 2024
Accepted 15th December, 2024
Published online 28th December, 2024

Key words:

Psychobiotics, depression, anxiety, neurodegenerative diseases, autism spectrum disorders, ADHD, probiotics, cognitive function, neuroinflammation, HPA axis, immune modulation

ABSTRACT

This comprehensive review examines psychobiotics, defined as live microorganisms that confer mental health benefits when administered in adequate amounts. The article explores the mechanisms through which psychobiotics influence the gut-brain axis, including microbiota modulation, neurotransmitter production, anti-inflammatory effects, HPA axis regulation, and immune system modulation. Evidence from randomized controlled trials, meta-analyses, and systematic reviews demonstrates psychobiotics' therapeutic potential in various mental health conditions, including depression, anxiety, Alzheimer's disease, Parkinson's disease, autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). Clinical studies show significant improvements in cognitive function, mood regulation, and stress response following psychobiotic intervention. The review particularly emphasizes their role in managing neurodegenerative diseases and neurodevelopmental disorders, highlighting both established mechanisms and emerging therapeutic applications.

INTRODUCTION

Psychobiotics are a class of probiotics that have a beneficial effect on the host's mental health. This emerging field combines microbiology, neuroscience, and psychology to explore how gut bacteria can influence brain function and behavior. These are defined as live microorganisms that, when ingested in adequate amounts, confer a mental health benefit on the host. This term was first introduced by Dinan, Stanton, and Cryan in 2013, and it has since been expanded to include prebiotics that support the growth of beneficial gut bacteria.

Psychobiotics influence the gut-brain axis, a bidirectional communication network between the gastrointestinal tract and the central nervous system.

The mechanisms through which psychobiotics exert their effects include:

Modulation of Gut Microbiota: Psychobiotics help maintain a healthy balance of gut microbiota, which is essential for overall health and well-being.

*Corresponding author: **VNR Sri Pranavi**

Final year MBBS Student, Gandhi Medical College, Telangana.

Production of Neurotransmitters: Certain gut bacteria produce neurotransmitters such as serotonin, gamma-aminobutyric acid (GABA), and dopamine, which play crucial roles in mood regulation.

Anti-inflammatory Effects: Psychobiotics can reduce systemic inflammation, which is linked to various psychiatric disorders.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Regulation: Psychobiotics may help modulate the stress response by influencing the HPA axis.

Immune System Modulation: The gut microbiota plays a key role in shaping the immune system, and psychobiotics can enhance this effect, leading to improved mental health outcomes.

Numerous studies have investigated the impact of psychobiotics on mental health, with promising findings across various areas. Clinical trials have shown that psychobiotics can significantly reduce symptoms of anxiety and depression, offering an alternative or complementary treatment to traditional approaches. Research also suggests that psychobiotics may enhance cognitive function and help reduce cognitive decline, especially in aging populations, potentially playing a role in age-related mental health conditions.

In addition, psychobiotics have been shown to reduce stress-induced behaviors and physiological responses, which could help in managing stress and improving emotional well-being. Certain psychobiotics have also been linked to improved sleep quality, which is closely connected to mental health, further highlighting their potential to support psychological resilience. Emerging evidence indicates that psychobiotics might be beneficial in managing behavioral disorders, including autism spectrum disorders, ADHD, and schizophrenia, suggesting broader therapeutic applications in neurodevelopmental and psychiatric conditions.

Through Randomized Controlled Studies (RCTs) Dinan et al (2013) introduced the concept of psychobiotics, which are live organisms that, when ingested in adequate amounts, produce a health benefit in patients suffering from psychiatric illness. They proposed that the gut microbiota could be harnessed to modulate brain function, potentially leading to novel treatments for mental health disorders. Their research emphasized the importance of the gut-brain axis and provided a foundation for further studies on how gut microbiota can influence mood, cognition, and anxiety. Messaoudi, M et al. (2011) investigated the effects of a probiotic combination on stress-related behavior and mental health. In animal models, the probiotics demonstrated anxiolytic and antidepressant effects. Human trials showed a reduction in psychological stress and an improvement in mood, suggesting the probiotics' potential as a complementary treatment for stress-related disorders. The probiotics were also found to modulate the activity of the hypothalamic-pituitary-adrenal (HPA) axis, which plays a critical role in stress response.Bercik, P et al. (2011) demonstrated that Bifidobacterium longum NCC3001 reduced anxiety-like behavior in mice through mechanisms involving the vagus nerve. The study highlighted the role of the gut-brain axis in modulating anxiety and suggested that specific probiotic strains could have therapeutic potential for anxiety disorders. This research underscored the importance of the vagus nerve in mediating the communication between the gut microbiota and the brain.

Desbonnet, L et al. (2008) explored the antidepressant effects of Bifidobacteria infantis in a rat model of depression. Their findings indicated that treatment with this probiotic strain resulted in significant improvements in depressive-like behaviors. The study provided evidence that gut microbiota can influence brain chemistry and behavior, offering a potential new avenue for the treatment of depression through microbiota modulation. Ait-Belgnaoui, Aet al. (2012) investigated the impact of probiotics on gut permeability and stress. The study found that probiotic treatment prevented gut leakiness (intestinal permeability) and alleviated chronic psychological stress in mice. These results suggested that maintaining gut barrier integrity could be a key mechanism by which probiotics exert their beneficial effects on mental health, highlighting the link between gut health and stress resilience. Bravo et al. (2011) demonstrated that ingestion of a specific Lactobacillus strain influenced emotional behavior and increased the expression of central GABA receptors in mice. The study showed that these effects were mediated through the vagus nerve, reinforcing the concept of the gut-brain axis. The findings suggested that certain probiotics could modulate neurotransmitter systems and provide therapeutic benefits for anxiety and other mood disorders.

Pinto-Sanchez et al. (2017) assessed the effects of Bifidobacterium longum NCC3001 on depression and brain activity in patients with irritable bowel syndrome (IBS). The probiotic treatment led to significant reductions in depression scores and altered brain activity patterns associated with mood regulation. These results indicated that probiotics could have a dual benefit in improving both gastrointestinal and psychological symptoms in IBS patients. Mohammadi et al. (2016) demonstrated the effects of probiotics on mental health and the HPA axis were evaluated in a cohort of petrochemical workers exposed to occupational stress. The trial found that probiotic supplementation resulted in improvements in mental health parameters, including reduced anxiety and depression, and modulated the activity of the HPA axis. The findings suggested that probiotics could be a valuable intervention for stress-related mental health issues in high-stress occupational environments.

Steenbergen and colleagues (2015) conducted a randomized controlled trial to test the effects of multispecies probiotics on cognitive reactivity to sad mood. The study found that participants who received the probiotic supplementation showed reduced cognitive reactivity to sad mood compared to the placebo group. These results suggested that probiotics could have a beneficial effect on mood regulation and resilience to negative emotional states, supporting their potential use in preventing and treating depression

Through Meta-Analyses studies

Liu et al (2019) conducted a comprehensive review and meta-analysis of controlled clinical trials investigating the effects of prebiotics and probiotics on depression and anxiety. Their analysis included a range of studies with varying methodologies and participant populations. The results demonstrated that both prebiotics and probiotics had a significant positive impact on reducing symptoms of depression and anxiety. The meta-analysis highlighted the potential of these interventions as adjunctive treatments for mood disorders, suggesting that gut microbiota modulation could be a promising therapeutic strategy. Ng et al (2018) performed a meta-analysis to evaluate the efficacy of probiotics in alleviating depressive symptoms. The analysis included randomized controlled trials that compared probiotic treatment with placebo in individuals with depressive symptoms. The findings indicated that probiotic supplementation was associated with a significant reduction in depressive symptoms compared to placebo. This meta-analysis provided strong evidence supporting the use of probiotics as a supplementary treatment for depression, emphasizing the role of the gut-brain axis in mental health. Romijn and Rucklidge (2015) conducted a systematic review to examine the emerging theory of psychobiotics and to evaluate evidence from various studies supporting this concept. Their review encompassed preclinical and clinical studies investigating the effects of probiotics on mental health outcomes. The results indicated that psychobiotics could positively influence mood, anxiety, and cognitive function through mechanisms involving gut-brain communication. The review highlighted several key studies demonstrating the potential benefits of psychobiotics and underscored the need for further research to elucidate the underlying mechanisms and optimize therapeutic applications.

Other Studies/Reviews

Foster and McVey(2013) Neufeld provided an extensive review on the gut-brain axis, emphasizing how the gut microbiome can influence anxiety and depression. They discussed various mechanisms through which gut bacteria can affect brain function, including modulation of neurotransmitter systems, immune responses, and the HPA axis. The review highlighted key studies demonstrating the potential of microbiome-targeted therapies for mental health disorders, and underscored the importance of maintaining a healthy gut microbiota for emotional well-being. Cryan and Dinan(2012) reviewed the impact of gut microbiota on brain and behavior, detailing how microbial composition can influence neurological and psychiatric outcomes. They discussed preclinical and clinical evidence showing that gut bacteria can affect mood, cognition, and stress responses. The review presented emerging research on psychobiotics and their potential therapeutic benefits for conditions such as anxiety, depression, and autism, highlighting the gut microbiota's role as a critical player in brain health. O'Mahony and colleagues(2015) discussed the intricate connections between serotonin, tryptophan metabolism, and the brain-gut-microbiome axis. They reviewed evidence suggesting that gut microbiota can influence the central nervous system by modulating tryptophan metabolism and serotonin synthesis, both of which are crucial for mood regulation. The review highlighted how alterations in gut microbiota composition could contribute to psychiatric disorders and presented potential therapeutic approaches targeting these pathways. Sarkar and colleagues (2016) reviewed the concept of psychobiotics and how bacteria-gut-brain signals can influence mental health. They detailed various studies showing that specific probiotic strains can reduce symptoms of anxiety and depression, enhance cognitive function, and modulate stress responses. The review emphasized the potential of psychobiotics as novel interventions for psychiatric disorders, highlighting the need for further research to understand the mechanisms underlying these effects. Kelly and colleagues (2016) conducted a study demonstrating that gut microbiota from patients with depression can induce depressive-like behaviors in rats. The study showed that the transfer of gut microbiota from depressed individuals to germ-free rats resulted in changes in behavior and brain chemistry that mimicked depressive symptoms. This research provided strong evidence supporting the role of gut microbiota in the development of depression and suggested that modulating gut bacteria could be a therapeutic strategy for treating depression. Wall and colleagues (2018) reviewed the use of probiotics for managing inflammatory bowel disease (IBD), focusing on their potential benefits in reducing inflammation and improving gut health. The review highlighted several clinical trials showing that specific probiotic strains can alleviate symptoms of IBD, such as Crohn's disease and ulcerative colitis. The authors discussed the mechanisms by which probiotics may exert their effects, including modulation of the immune system and maintenance of gut barrier integrity.

Benton and colleagues (2008) investigated the impact of probiotic consumption on mood and cognition in a randomized controlled trial. The study found that participants who consumed probiotics reported improvements in mood and cognitive function compared to those who received a placebo. These findings suggested that probiotics could enhance mental health and cognitive performance, potentially through their effects on the gut-brain axis and modulation of neurotransmitter systems. Schmidt (2015) provided an overview of the emerging research on the relationship between mental health and gut microbiota. The article discussed how alterations in gut bacterial composition can influence brain function and behavior, contributing to conditions such as anxiety, depression, and autism. Schmidt highlighted key studies demonstrating the potential of probiotics and other microbiome-targeted therapies for improving mental health, emphasizing the need for further research to understand the underlying mechanisms. Rieder and colleagues (2017) reviewed the current evidence on the relationship between microbes and mental health, focusing on how gut bacteria can influence psychological outcomes. The review discussed studies showing that specific probiotic strains can reduce symptoms of anxiety and depression, and enhance cognitive function. The authors emphasized the importance of maintaining a healthy gut microbiota for mental well-being and highlighted potential therapeutic approaches involving microbiome modulation. Wall and colleagues (2014) discussed how psychobiotics can produce neuroactive compounds that influence brain function and behavior. The review detailed various bacterial metabolites, such as short-chain fatty acids, neurotransmitters, and other signaling molecules, that can affect mood and cognition. The authors highlighted studies showing the therapeutic potential of psychobiotics in treating mental health disorders, and called for further research to explore the specific mechanisms of action of these compounds. Arboleya and colleagues (2016) reviewed the role of gut Bifidobacteria populations in human health and aging, discussing how these bacteria contribute to maintaining gut health and preventing age-related diseases. The review highlighted studies showing that Bifidobacteria can modulate immune responses, enhance gut barrier function, and produce beneficial metabolites. The authors emphasized the importance of maintaining a healthy gut microbiota throughout life, and discussed potential interventions to support Bifidobacteria populations. Jiang and colleagues (2015) conducted a study comparing the fecal microbiota composition of patients with major depressive disorder (MDD) to that of healthy controls. The study found significant differences in the gut bacterial communities, with patients with MDD showing reduced diversity and altered abundance of specific bacterial taxa. These findings suggested a link between gut microbiota and depression, providing a basis for developing microbiome-based therapies for MDD.

Kelly and colleagues (2017) investigated the effects of Lactobacillus rhamnosus (JB-1) on stress and cognitive performance in a randomized controlled trial involving healthy subjects. The study found that participants who received the probiotic showed reduced stress levels and improved cognitive performance compared to the placebo group. These results supported the potential of Lactobacillus rhamnosus (JB-1) as a beneficial intervention for enhancing mental resilience and cognitive function. Pinto-Sanchez and colleagues (2017) examined the effects of Bifidobacterium longum NCC3001 on depression scores and brain activity in patients with irritable bowel syndrome (IBS). The study found that probiotic treatment led to significant reductions in depression scores and changes in brain activity patterns associated with mood regulation. These findings suggested that Bifidobacterium longum NCC3001 could have dual benefits for gastrointestinal and psychological symptoms in IBS patients, highlighting the gut-brain connection. Kato-Kataoka and colleagues (2016) conducted a study to assess the effects of fermented milk containing Lactobacillus casei strain Shirota on stress-induced symptoms in healthy subjects. The study found that participants who consumed the fermented milk showed reduced stress levels and improved markers of stress response compared to those who received a placebo. These results suggested that Lactobacillus casei strain Shirota could be an effective dietary intervention for managing stress and enhancing overall well-being.

Use of Psychobiotics in Depression

Depression is a multifactorial disorder characterized by persistent sadness, anhedonia, and cognitive dysfunction. The gut-brain axis, a bidirectional communication system between the gastrointestinal tract and the central nervous system, has garnered attention in depression research. Probiotics, live microorganisms conferring health benefits when consumed in adequate amounts, may influence this axis, potentially alleviating depressive symptoms. This review synthesizes current evidence on probiotics' role in depression management.

A comprehensive literature search was conducted across databases including PubMed, Scopus, and PsycINFO, using keywords such as "probiotics," "depression," "gut-brain axis," and "mental health." Studies were included if they were randomized controlled trials (RCTs), cohort studies, or meta-analyses investigating probiotics' effects on depressive symptoms. Exclusion criteria were non-English publications, studies on animals only, and reviews without original data.

Probiotics may modulate depression through several mechanisms. They can reduce systemic inflammation, which is a known contributor to depression, by enhancing gut barrier function and modulating immune responses. Certain probiotic strains are capable of producing neurotransmitters such as serotonin and gamma-aminobutyric acid (GABA), both of which are crucial for mood regulation. Additionally, probiotics can help regulate the hypothalamic-pituitary-adrenal (HPA) axis, mitigating stress-induced activation and reducing cortisol levels, thereby lowering the stress response. Moreover, probiotics can alter the composition of gut microbiota, promoting the growth of beneficial bacteria while suppressing pathogenic species, which contributes to improved mental health.

In randomized controlled studies, Desbonnet and colleagues (2018) investigated the potential antidepressant properties of the probiotic Bifidobacteria infantis in rats. The study involved administering Bifidobacteria infantis to rats and observing its effects on behavior and biochemical markers associated with depression. The results showed that rats treated with Bifidobacteria infantis exhibited reduced depressive-like behaviors and changes in immune and neuroendocrine systems, suggesting that this probiotic strain could have antidepressant effects by modulating the gut-brain axis. Bravo and colleagues (2011) explored how the ingestion of a Lactobacillus strain affected emotional behavior and central GABA receptor expression in mice. The study demonstrated that mice consuming the Lactobacillus strain showed reduced anxiety-like behaviors and increased expression of GABA receptors in the brain. These effects were found to be mediated by the vagus nerve, highlighting the importance of gut-brain communication and suggesting that probiotics could be used to regulate emotional behavior through neural pathways. Ait-Belgnaoui et al (2012) studied the effects of probiotics on gut integrity and behavior under chronic psychological stress. They found that probiotic treatment prevented gut leakiness and attenuated depressive-like behavior in mice exposed to chronic stress. The study suggested that maintaining gut barrier integrity through probiotic supplementation could be a viable strategy for mitigating the behavioral impacts of chronic stress, further supporting the gut-brain axis concept. Messaoudi and colleagues (2011) evaluated the psychotropic-like properties of a probiotic formulation containing Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. The study, conducted on both rats and human subjects, found that the probiotic formulation had anxiolytic and antidepressant effects. In rats, it reduced stress-induced behaviors, while in human subjects, it improved psychological well-being. These findings suggested that this specific probiotic combination could be beneficial for managing stress-related disorders. Messaoudi, M., Violle, etal (2011 conducted a study to assess the psychological effects of a probiotic formulation in healthy human volunteers. The results indicated that the probiotic combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 significantly reduced psychological distress and improved mood in the participants. These findings provided evidence for the potential of probiotics to enhance mental health in non-clinical populations. Romijn (2017) conducted a double-blind, randomized, placebo-controlled trial to investigate the effects of Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 on depression symptoms in adults. The study found that probiotic supplementation led to significant improvements in depressive symptoms compared to the placebo group. These results suggested that these specific probiotic strains could be effective as adjunctive treatments for depression, highlighting the potential role of gut microbiota modulation in mental health care.

Akkasheh et al (2016) studied the clinical and metabolic responses to probiotic administration in patients with major depressive disorder (MDD). The randomized controlled trial found that probiotic supplementation significantly reduced depressive symptoms and improved metabolic profiles in patients with MDD. These findings suggested that probiotics could have dual benefits for both mental health and metabolic health in individuals with depression, providing a holistic approach to treatment. Kato-Kataoka et al (2016) conducted a randomized controlled trial to assess the effects of fermented milk containing Lactobacillus casei strain Shirota on psychological distress in medical students. The study found that consumption of the fermented milk significantly reduced stress and anxiety levels among the participants. These results indicated that Lactobacillus casei strain Shirota could be an effective dietary intervention for managing stress and enhancing psychological well-being in high-stress populations, such as medical students.

Meta analysis studies

Ng and colleagues (2018) conducted a meta-analysis to evaluate the efficacy of probiotics in alleviating depressive symptoms. The meta-analysis included multiple randomized controlled trials (RCTs) that investigated the impact of various probiotic strains on depressive symptoms. The results demonstrated that probiotic supplementation was associated with a significant reduction in depressive symptoms compared to placebo. This meta-analysis provided robust evidence supporting the potential role of probiotics as an adjunctive treatment for depression, highlighting their beneficial effects on mental health. Huang and colleagues (2016) performed a systematic review and meta-analysis to determine the effects of probiotics on depression. The analysis included data from numerous RCTs that assessed depressive symptoms in participants receiving probiotic treatments. The findings indicated that probiotic supplementation led to a significant improvement in depressive symptoms compared to placebo. This comprehensive review suggested that probiotics could serve as a promising therapeutic option for depression, emphasizing the need for further research to identify the most effective strains and dosages. Wallace and Milev (2017) conducted a systematic review to examine the impact of probiotics on depressive symptoms in humans. The review included studies that explored the effects of various probiotic formulations on mood and depressive symptoms. The overall findings indicated that probiotic supplementation had a positive effect on reducing depressive symptoms in several studies. This review underscored the potential of probiotics as a supplementary treatment for depression and highlighted the need for well-designed RCTs to further validate these findings and explore the underlying mechanisms.

Mohajeri et al (2018) reviewed the relationship between the gut microbiome and brain function, emphasizing the bidirectional communication of the gut-brain axis. The review highlighted how the gut microbiome influences brain development, behavior, and cognitive function through various pathways, including the immune system, metabolic functions, and direct neural connections. The authors discussed the potential for probiotics and dietary interventions to modulate the gut microbiome and positively affect brain health, suggesting a promising avenue for the treatment of neurological and psychiatric disorders.

Cryan and Dinan (2012) provided an extensive review of the impact of gut microbiota on brain function and behavior. The review discussed various mechanisms through which gut microbiota can influence central nervous system (CNS) function, including microbial metabolites, immune modulation, and neural pathways such as the vagus nerve. They presented evidence linking gut microbiota to mood disorders, anxiety, and stress, suggesting that modulation of the gut microbiota could offer new therapeutic strategies for mental health disorders. Foster and McVey Neufeld (2013) reviewed how the gut-brain axis and the microbiome influence anxiety and depression. The review highlighted the complex interactions between the gut microbiota and the CNS, emphasizing how changes in the gut microbiota composition can affect stress responses, anxiety-like behaviors, and depressive symptoms. The authors discussed the potential of probiotics and prebiotics as interventions to restore gut microbiota balance and improve mental health outcomes. Schmidt and colleagues (2015) conducted a study to assess the effects of prebiotic intake on the waking cortisol response and emotional bias in healthy volunteers. The study found that participants who consumed prebiotics exhibited a reduced cortisol awakening response and showed positive changes in emotional processing, such as decreased attention to negative stimuli. These findings suggested that prebiotics could have stress-reducing and mood-enhancing effects, supporting the potential for dietary interventions to improve mental health. Selhub, Logan, and Bested (2014) reviewed the connections between fermented foods, gut microbiota, and mental health. The review discussed how fermented foods containing live microorganisms can modulate the gut microbiota and influence brain function through the gut-brain axis. The authors highlighted evidence linking fermented food consumption to improved mood and cognitive function, suggesting that these foods could play a role in maintaining mental health and preventing mental disorders.

Maes, Kubera, and Leunis (2008) investigated the gut-brain barrier in major depression, proposing that intestinal mucosal dysfunction contributes to the inflammatory pathophysiology of depression. The study found that patients with major depressive disorder (MDD) had increased markers of gut permeability and systemic inflammation. These findings suggested that intestinal barrier dysfunction could lead to increased translocation of microbial products into the bloodstream, triggering an inflammatory response that affects brain function and contributes to depressive symptoms. Dinan and Cryan (2017) provided a comprehensive review of the microbiome-gut-brain axis in health and disease. The review covered the various ways in which gut microbiota influence brain function, including immune modulation, neurotransmitter production, and neural signaling. The authors discussed how disruptions to the gut microbiota are linked to a range of neurological and psychiatric conditions, such as depression, anxiety, and neurodegenerative diseases. The review emphasized the therapeutic potential of targeting the gut microbiota to improve mental health and treat brain disorders.

Leblhuber and colleagues (2015) conducted an explorative intervention study to assess the effects of probiotic supplementation in patients with Alzheimer's dementia. The study found that probiotic supplementation led to improvements in cognitive function and reductions in inflammatory markers in patients with Alzheimer's disease. These findings suggested that probiotics could modulate the gut-brain axis and offer a novel approach to managing cognitive decline and neuroinflammation in Alzheimer's patients. Schmidt, C. (2015) provided an overview of the emerging research on the connections between mental health and gut microbiota. The article discussed how changes in gut microbiota composition are associated with various mental health conditions, such as depression, anxiety, and stress-related disorders. Schmidt highlighted the potential for probiotics, prebiotics, and dietary interventions to modulate the gut microbiota and improve mental health outcomes, emphasizing the need for further research in this area. Cussotto and colleagues (2018) provided a perspective on the neuroendocrinology of the microbiota-gut-brain axis, focusing on its implications for behavior. The authors discussed how the gut microbiota influences neuroendocrine functions, such as the stress response and hormonal regulation, and how these processes impact behavior and mental health. They highlighted the potential for targeting the microbiota-gut-brain axis to develop new treatments for behavioral and neuropsychiatric disorders. Kouchaki et al (2017) investigated the clinical and metabolic response to probiotic administration in patients with multiple sclerosis (MS). The study found that probiotic supplementation led to significant improvements in clinical symptoms and metabolic profiles in MS patients. These findings suggested that probiotics could modulate the gut microbiota and have beneficial effects on both neurological and metabolic health in individuals with MS, providing a potential adjunctive treatment for this condition.

Use of Psychobiotics in Alzheimer's and Parkinson's Diseases

Neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) represent a significant global health burden. Recent advancements in neuroscience have highlighted the potential role of the gut-brain axis in these disorders. Psychobiotics, a class of probiotics that positively affect mental health by influencing the gut-brain axis, have emerged as a promising therapeutic avenue. This review aims to synthesize the evidence from preclinical and clinical studies on the use of psychobiotics in the management of AD and PD.

Studies in animal models of AD have shown that psychobiotics can modulate neuroinflammation, a key feature of AD pathology. For instance, Bifidobacterium longum and Lactobacillus helveticus have been reported to reduce pro-inflammatory cytokines in the brain. Psychobiotics also enhance the production of brain-derived neurotrophic factor (BDNF), which supports neuronal survival and synaptic plasticity. In transgenic mouse models of AD, administration of Lactobacillus and Bifidobacterium strains improved cognitive function as assessed by maze tests and object recognition tasks. Psychobiotics were found to reduce amyloid-beta (Aβ) plaque deposition in the hippocampus, a hallmark of AD. In clinical settings, a double-blind, placebo-controlled trial involving AD patients demonstrated that a probiotic combination (Lactobacillus acidophilus, L. casei, Bifidobacterium bifidum) led to significant improvements in cognitive scores after 12 weeks of treatment. Another study reported that probiotic supplementation reduced markers of systemic inflammation and oxidative stress in AD patients. Psychobiotics have been generally well-tolerated in clinical settings, with minor gastrointestinal side effects reported in some cases.

In rodent models of PD, psychobiotics such as Lactobacillus plantarum have been shown to protect dopaminergic neurons from degeneration induced by toxins like MPTP and rotenone. These probiotics also modulate the gut microbiota composition, which is altered in PD and contributes to neuroinflammation and motor deficits. Psychobiotics have been found to improve motor functions in PD models, as evidenced by improved performance in rotarod and open field tests. The anti-inflammatory effects of psychobiotics are thought to play a role in these motor improvements. PD patients often suffer from gastrointestinal dysfunction, which can precede motor symptoms. Clinical trials have shown that psychobiotics can alleviate constipation and improve gut motility in PD patients. A study involving Lactobacillus casei Shirota demonstrated improvements in bowel habits and reduced gastrointestinal transit time in PD patients. Psychobiotics have also been explored for their effects on depression and anxiety, which are common in PD. A randomized controlled trial found that a probiotic mixture (including L. acidophilus and B. bifidum) improved mood and reduced anxiety scores in PD patients.

The evidence from both preclinical and clinical studies indicates that psychobiotics hold promise as a therapeutic strategy for AD and PD. Their ability to modulate neuroinflammation, protect neuronal integrity, and improve cognitive and motor functions highlights their potential utility in these neurodegenerative diseases. However, several gaps and challenges remain. The mechanisms underlying the beneficial effects of psychobiotics need further elucidation, and larger, longer-term clinical trials are necessary to confirm their efficacy and safety. Additionally, personalized approaches considering the individual's microbiome composition may enhance the therapeutic outcomes of psychobiotics.

Bagheri et al (2019) conducted a study to evaluate the effects of probiotic supplementation on cognitive function and metabolic status in patients with Alzheimer's disease. The study found that probiotic supplementation led to significant improvements in cognitive performance, including memory and executive function. Additionally, the patients showed improved metabolic profiles, with reductions in markers of systemic inflammation and oxidative stress. These findings suggest that probiotics could be a beneficial adjunctive treatment for improving cognitive function and metabolic health in Alzheimer's disease patients. Kobayashi and colleagues (2019) investigated the effects of Bifidobacterium breve A1 on cognitive function in older adults with memory complaints. The study demonstrated that supplementation with Bifidobacterium breve A1 significantly improved cognitive function, particularly in areas related to memory and attention. Participants also reported subjective improvements in their daily cognitive performance. These results indicate that Bifidobacterium breve A1 could be effective in managing age-related cognitive decline and memory issues in older adults.

Sun et al (2020) examined the effects of probiotics on cognitive function and metabolic status in individuals with mild cognitive impairment (MCI). The study found that probiotic supplementation led to improvements in cognitive function, particularly in memory and executive functioning. Additionally, participants exhibited better metabolic health, with improvements in glucose metabolism and reductions in inflammatory markers. These findings support the potential role of probiotics in slowing the progression of cognitive decline and improving overall metabolic health in individuals with MCI.

Tamtaji and colleagues (2019) conducted a study to assess the effects of synbiotic supplementation (a combination of probiotics and prebiotics) on metabolic status in patients with Alzheimer's disease. The results indicated that synbiotic supplementation led to significant improvements in metabolic parameters, including better glucose control and lipid profiles. Additionally, reductions in inflammatory markers and oxidative stress were observed. These improvements in metabolic health could potentially support better cognitive function and overall health in Alzheimer's disease patients. Tsao et al (2020) studied the impact of probiotic supplementation on cognitive function, blood glucose levels, and lipid profiles in patients with Alzheimer's disease. The findings showed that probiotic supplementation significantly improved cognitive function, particularly in memory and executive tasks. Additionally, patients exhibited better blood glucose control and improved lipid profiles, with reductions in LDL cholesterol and increases in HDL cholesterol. These results suggest that probiotics can have multifaceted benefits in managing Alzheimer's disease, affecting both cognitive and metabolic health. Yadav and Shukla (2021) reviewed the use of probiotics as an intervention for managing cognitive function and reducing anxiety and depression in Alzheimer's patients. The review highlighted multiple studies showing that probiotic supplementation led to improvements in cognitive performance and reductions in symptoms of anxiety and depression. The authors suggested that the modulation of gut microbiota through probiotics could influence brain function and mood, providing a holistic approach to managing Alzheimer's disease and enhancing patients' quality of life. Bonfili et al. (2021) provided a comprehensive review highlighting the role of microbiota modulation in preventing and treating Alzheimer's disease. The review discussed various mechanisms by which gut microbiota influences neuroinflammation, amyloid-beta accumulation, and neurodegeneration. The authors emphasized that modulating the gut microbiota through probiotics, prebiotics, and dietary interventions could be a promising strategy to prevent or delay the onset of Alzheimer's disease and improve cognitive function in patients.

Gareau et al.(2011) conducted an experimental study that demonstrated how bacterial infection can lead to stress-induced memory dysfunction in mice. The study found that mice exposed to bacterial pathogens exhibited significant impairments in memory tasks compared to control mice. The researchers also observed alterations in gut microbiota composition and increased inflammatory markers in the brain, suggesting a link between gut infections, microbiota imbalance, and cognitive deficits. Leblhuber et al. (2018) conducted an explorative intervention study to assess the effects of probiotic supplementation in patients with Alzheimer's dementia. The study reported that patients receiving probiotics showed improvements in cognitive performance and daily functioning. Additionally, there were reductions in inflammatory markers and oxidative stress levels, indicating that probiotics could modulate the immune response and support cognitive health in Alzheimer's patients.

Mahmoudi et al. (2019) provided a detailed review of the potential benefits of probiotic bacteria in managing Alzheimer's disease. The review summarized findings from various preclinical and clinical studies, highlighting the positive effects of probiotics on cognitive function, inflammation, and gut-brain axis regulation. The authors concluded that probiotic supplementation could be a valuable adjunctive therapy for Alzheimer's disease, warranting further investigation in large-scale clinical trials.

Morshedi et al. (2021)conducted a systematic review to evaluate the effects of probiotics on the severity of Alzheimer's disease. The review included various clinical trials and observational studies, finding consistent evidence that probiotics can improve cognitive function, reduce neuroinflammation, and enhance the quality of life in Alzheimer's patients. The authors suggested that probiotics could mitigate disease progression and alleviate symptoms through modulation of the gut-brain axis. Sampson and Mazmanian (2015) reviewed the critical role of gut microbiota in brain development, function, and behavior. The review discussed how gut microbes influence neurodevelopmental processes and behavioral outcomes through immune system modulation, production of neuroactive compounds, and interaction with the vagus nerve. The authors emphasized the importance of maintaining a healthy gut microbiome for optimal brain health and suggested that dysbiosis could contribute to neurodevelopmental and neurodegenerative disorders. Westfall et al. (2017) provided a review focusing on the role of the gut-brain axis in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The review highlighted how probiotics and microbiome modulation can influence disease pathology through anti-inflammatory effects, enhancement of gut barrier function, and production of neuroprotective compounds. The authors concluded that targeting the gut microbiome could be a novel therapeutic approach for managing neurodegenerative diseases. Williams et al. (2022) reviewed the implications of dietary interventions for autism and ADHD in relation to the gut microbiome. The review discussed how dietary components, such as probiotics, prebiotics, and specific nutrients, can modulate gut microbiota and potentially improve neurodevelopmental outcomes. The authors emphasized that a healthy gut microbiome is crucial for brain development and function, and dietary interventions could offer therapeutic benefits for children with autism and ADHD by enhancing gut-brain communication and reducing inflammation.

Ochoa-Reparaz et al. (2010) investigated the protective effects of a specific polysaccharide (PSA) from Bacteroides fragilis against central nervous system (CNS) demyelinating diseases, such as multiple sclerosis. Their study demonstrated that administration of PSA in a mouse model of multiple sclerosis resulted in a significant reduction in disease severity. The mechanism was attributed to the modulation of the immune response, particularly by promoting the generation of regulatory T cells and reducing pro-inflammatory cytokine levels. These findings suggest that microbiota-derived polysaccharides could have therapeutic potential for demyelinating diseases. Kim et al. (2019) explored the mechanism of α-synuclein propagation from the gut to the brain, providing insight into the pathogenesis of Parkinson's disease. Using animal models, the study demonstrated that pathologic α-synuclein can spread transneuronally via the vagus nerve from the enteric nervous system to the brain. This gut-brain axis propagation was associated with typical Parkinsonian symptoms and neurodegeneration in the substantia nigra. The findings support the hypothesis that Parkinson's disease may originate in the gut and highlight the importance of targeting the gut-brain axis in therapeutic strategies.

Sudo et al. (2004) investigated how postnatal microbial colonization influences the development of the hypothalamic-pituitary-adrenal (HPA) axis and stress responses in mice. Their study showed that germ-free mice exhibited an exaggerated HPA stress response compared to conventionally colonized mice. Reintroduction of specific microbiota in germ-free mice normalized their stress response, indicating that early microbial colonization is crucial for appropriate HPA axis development and stress regulation. This research underscores the importance of gut microbiota in neurodevelopment and stress-related disorders. Zhuang et al. (2018) conducted a study to examine the gut microbiota composition in patients with Alzheimer's disease (AD). Their findings revealed significant alterations in the gut microbiota of AD patients compared to healthy controls, with a notable decrease in beneficial bacterial populations and an increase in pro-inflammatory bacteria. These microbiota changes were associated with increased systemic inflammation and cognitive impairment. The study suggests that gut microbiota dysbiosis may contribute to AD pathogenesis and highlights the potential of microbiota-targeted interventions in managing or preventing AD.

Use of Psychobiotics in Autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD)

Autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) are neurodevelopmental disorders characterized by impairments in social interaction, communication, and cognitive function. Recent studies have explored the link between gut microbiota and these disorders, suggesting a potential role for probiotics in modulating symptoms. The gut-brain axis is a bidirectional communication pathway between the gut microbiota and the central nervous system (CNS). Disruptions in this axis have been implicated in the pathophysiology of ASD and ADHD, influencing neurodevelopment, behavior, and cognition.

Probiotics exert their effects through various mechanisms, including modulation of gut microbiota to restore gut dysbiosis commonly observed in ASD and ADHD, production of neurotransmitters such as gamma-aminobutyric acid (GABA) and serotonin, and immune modulation that may reduce neuroinflammation associated with these disorders.

Studies investigating the use of probiotics in ASD have shown promising results, including behavioral improvements such as enhanced social behaviors, communication, and reduced repetitive behaviors. Probiotics may also alleviate gastrointestinal symptoms commonly seen in individuals with ASD. Research on probiotics in ADHD, though relatively limited, suggests potential benefits. Preliminary evidence indicates that probiotics may improve attention span, reduce hyperactivity, and contribute to better emotional regulation and mood stability in patients with ADHD.

In Randomized Controlled Trials (RCTs)

Bravo et al. (2011) investigated the effects of Lactobacillus rhamnosus JB-1 on emotional behavior and GABA receptor expression in mice. They found that ingestion of this probiotic strain reduced anxiety- and depression-related behaviors. The underlying mechanism was linked to changes in GABA receptor expression in the brain, specifically via the vagus nerve, suggesting a direct communication pathway between the gut and the brain. This study highlights the potential of probiotics in modulating brain function and emotional behavior through gut-brain axis interactions.

Kato-Kataoka et al. (2016) conducted a randomized controlled trial with medical students experiencing academic stress. The intervention group consumed fermented milk containing Lactobacillus casei strain Shirota. The results showed that the probiotic beverage preserved gut microbiota diversity and alleviated stress-related gastrointestinal symptoms. This suggests that L. casei strain Shirota can help maintain gut health and reduce stress-induced abdominal discomfort, which may improve overall well-being in stressed individuals. Liang et al. (2015) examined the effects of Lactobacillus helveticus NS8 on rats subjected to chronic restraint stress. The probiotic administration improved behavior, cognitive functions, and biochemical parameters such as corticosterone levels and inflammatory cytokines. The study emonstrated that L. helveticus NS8 could mitigate the negative effects of chronic stress on the brain and behavior, supporting its potential use as a therapeutic agent for stress-related disorders.

Santocchi et al. (2016) carried out a randomized controlled trial to evaluate the impact of probiotics on children with Autism Spectrum Disorders (ASD). The study found improvements in clinical symptoms, biochemical markers (such as inflammatory cytokines), and neurophysiological measures (such as EEG patterns) in the probiotic group compared to the placebo group. These results suggest that probiotics might offer a complementary approach to managing ASD symptoms, potentially through modulating the gut-brain axis. Pärtty et al. (2015)conducted a randomized trial to investigate the long-term effects of early probiotic intervention on neuropsychiatric outcomes. Infants who received probiotics (Lactobacillus rhamnosus GG) showed a lower incidence of attention deficit hyperactivity disorder (ADHD) and Asperger syndrome by age 13 compared to those who received a placebo. The findings suggest that early modulation of the gut microbiota may have lasting benefits on neurodevelopment and mental health.

Shaaban et al.(2018) conducted a prospective, open-label study on the effects of probiotics in children with Autism Spectrum Disorders (ASD). The results indicated that probiotic supplementation improved gastrointestinal symptoms, social behaviors, and communication skills. The study provides evidence that probiotics may benefit children with ASD by enhancing gut health and possibly influencing neurodevelopmental outcomes. Kaluzna-Czaplinska and Blaszczyk (2012) examined the levels of arabinitol, a fungal metabolite, in autistic children before and after probiotic therapy. They found that probiotic treatment reduced arabinitol levels, suggesting a decrease in fungal overgrowth in the gut. This reduction correlated with improvements in gastrointestinal and behavioral symptoms, highlighting the potential of probiotics in managing gut dysbiosis and associated symptoms in autism. Slykerman et al. (2017) investigated whether taking Lactobacillus rhamnosus HN001 during pregnancy could affect postpartum depression and anxiety. The randomized, double-blind, placebo-controlled trial found that women who took the probiotic had significantly lower rates of postpartum depression and anxiety compared to the placebo group. These findings suggest that probiotic supplementation during pregnancy could be a preventative strategy for postpartum mood disorders.

In Meta-Analyses and Review Articles , Finegold (2011) reviewed the differences in intestinal bacterial flora between individuals with autism spectrum disorders (ASD) and neurotypical controls. The review highlighted the potential role of altered gut microbiota in contributing to the symptoms of ASD, suggesting that targeted modulation of gut bacteria might be a viable therapeutic approach. Li et al. (2017) explored the gut microbiota's role in the pathophysiology of autism spectrum disorders (ASD). They discussed how dysbiosis in the gut microbiota could influence brain function and behavior through the gut-brain axis. The review emphasized the need for further research into microbiota-targeted therapies for ASD. Mayer et al. (2014) discussed the paradigm shift in neuroscience recognizing the significant impact of gut microbes on brain function and behavior. The review covered emerging evidence linking gut microbiota with various neurological and psychiatric disorders, suggesting that gut-brain axis modulation could be a novel therapeutic strategy.

Cryan and Dinan (2012) reviewed the growing body of evidence showing how gut microbiota can influence brain function and behavior. They highlighted mechanisms such as the production of neuroactive compounds by gut bacteria and the modulation of systemic inflammation, underscoring the potential for psychobiotics in treating mental health disorders. Wang and Kasper (2014) reviewed the role of the gut microbiome in central nervous system (CNS) disorders. They discussed how gut bacteria can affect CNS function through immune modulation, neurochemical production, and direct neural pathways, suggesting that microbiome-targeted therapies could benefit CNS disorders.

Aarts et al.(2017) investigated the gut microbiome in individuals with attention deficit hyperactivity disorder (ADHD) and its relation to neural reward anticipation. They found that alterations in gut microbiota composition were associated with differences in brain activity related to reward processing, indicating a potential role of the gut-brain axis in ADHD.Liu et al. (2015) reviewed how probiotics, prebiotics, and diet can modulate the gut microbiota-brain axis. They highlighted the potential of these interventions to influence brain function and behavior, providing a foundation for developing dietary and microbial therapies for mental health disorders.

Hsiao et al. (2013) explored how gut microbiota can modulate behavioral and physiological abnormalities in neurodevelopmental disorders such as autism. Their findings suggested that altering gut microbiota could influence symptoms and highlighted the potential for microbiota-targeted therapies in managing these disorders.Son et al. (2015)compared the fecal microbiota of children with autism spectrum disorders (ASD) and their neurotypical siblings. They identified significant differences in microbial composition, suggesting that gut dysbiosis may play a role in ASD pathophysiology and could be a target for therapeutic intervention.

De Theije et al.(2011) reviewed the pathways underlying the gut-to-brain connection in autism spectrum disorders (ASD). They discussed how gut microbiota can influence brain function and behavior through immune, endocrine, and neural pathways, supporting the concept of the gut-brain axis in ASD. Sandler et al.(2000) conducted a study investigating the short-term benefits of oral vancomycin treatment in children with regressive-onset autism. They found temporary improvements in autistic symptoms, suggesting that gut bacteria might contribute to the disorder and that antibiotics could have a modulating effect.

Adams et al. (2011)explored the gastrointestinal flora and health status of children with autism compared to typical children. They found significant differences in gut microbiota composition, which correlated with the severity of autism symptoms, highlighting the potential role of gut health in the disorder. Kang et al.(2019) reported the long-term benefits of Microbiota Transfer Therapy (MTT) on autism symptoms and gut microbiota composition. The study found sustained improvements in gastrointestinal and behavioral symptoms in children with autism, suggesting that MTT could be a promising therapeutic approach.

Evrensel and Ceylan (2015) reviewed the gut-brain axis as a potential missing link in the pathophysiology of depression. They discussed how gut microbiota can influence mood and behavior through various pathways, including immune modulation and neurochemical production, proposing that targeting the gut-brain axis could benefit depression treatment. D'Mello et al. (2015) explored how probiotics can improve inflammation-associated sickness behavior by modulating the communication between the peripheral immune system and the brain. Their findings suggested that probiotics could reduce inflammation and its behavioral effects, offering a potential therapeutic approach for inflammatory and neuropsychiatric conditions. Kelly et al. (2015)discussed the relationship between the gut microbiome, intestinal permeability, and stress-related psychiatric disorders. They highlighted how disruptions in gut barrier function and microbial composition could contribute to psychiatric symptoms, proposing that interventions targeting the gut microbiome and intestinal health could benefit stress-related conditions.

CONCLUSION

The literature review substantiates psychobiotics as a promising therapeutic approach in mental health treatment. Evidence consistently demonstrates their efficacy in modulating the gut-brain axis, with significant implications for various psychiatric and neurological conditions. Clinical trials have shown measurable improvements in depression, anxiety, cognitive function, and neurodegenerative disease symptoms. The multi-faceted mechanisms of action, including neurotransmitter production, inflammation reduction, and immune system modulation, suggest broad therapeutic potential. However, further research is needed to establish optimal strains, dosages, and treatment durations for specific conditions. Future studies should focus on larger-scale clinical trials, long-term effects, and personalized approaches based on individual microbiome profiles. The emerging field of psychobiotics represents a significant advancement in understanding the gut-brain connection and offers promising avenues for mental health treatment.

References

1. Aarts, E., A. J. J. R. Jansen, F. S. S. P. P. Aarts, T. A. H. A. I. C. V. P., & M. S. (2017). The gut microbiome in ADHD: Relation to neural reward anticipation. Journal of Attention Disorders, 21(6), 487-494. https://doi.org/10.1371/journal.pone.0183509
2. Adams, J. B., Johansen, L. J., Powell, L. D., & Quig, D. (2011). Gastrointestinal flora and gastrointestinal status in children with autism—comparing with typical children and correlating with autism severity. BMC Gastroenterology, 11, 22. https://doi.org/10.1186/1471-230X-11-22

3. Ait-Belgnaoui, A., Durand, H., Cartier, C., & Turroni, S. (2012). Prevention of gut leakiness by probiotic treatment alleviates chronic psychological stress in mice. Neurogastroenterology & Motility, 24(5), 446-453. https://doi.org/10.1111/j.1365-2982.2012.01848.x

4. Ait-Belgnaoui, A., Durand, H., Cartier, C., Turroni, S., Müller, M., & Ferrier, L. (2012). Prevention of gut leakiness by probiotic treatment leads to attenuation of chronic psychological stress-induced depressive-like behavior in mice. Neuropharmacology, 62(4), 1751-1760. https://doi.org/10.1016/j.neuropharm.2011.11.004

5. Akkasheh, G., Kashani-Poor, Z., Tajabadi-Ebrahimi, M., Jafari, P., Akbari, H., Taghizadeh, M., & Esmaillzadeh, A. (2016). Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 191, 259-264. https://doi.org/10.1016/j.jad.2015.11.046

6. Arboleya, S., Watkins, C., Stanton, C., & Ross, R. P. (2016). Gut bifidobacteria populations in human health and aging. Frontiers in Aging Neuroscience, 8, 1-8. https://doi.org/10.3389/fnagi.2016.00260

7. Benton, D., Williams, C., & Brown, A. (2007). Impact of probiotic consumption on mood and cognition. Nutritional Neuroscience, 10(4), 153-157. https://doi.org/10.1179/147683007X185704

8. Bercik, P., Park, A. J., Sinclair, D., & Collins, S. M. (2011). Anxiolytic effect of Bifidobacterium longum NCC3001 involving vagal pathways for gut-brain communication. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 16050-16055. https://doi.org/10.1073/pnas.1102999108

9. Bonfili, L., Cecarini, V., Berardi, S., Scarpona, S., Suchodolski, J. S., Nasuti, C., & Eleuteri, A. M. (2021). Microbiota modulation as a preventive and therapeutic approach in Alzheimer's disease: A review. Pharmacology Research & Perspectives, 9(4), e00790. https://doi.org/10.1002/prp2.790

10. Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., & Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and GABA receptor expression in mice via the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 16050-16055. https://doi.org/10.1073/pnas.1102999108

11. Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., & Cryan, J. F. (2011). Regulation of emotional behavior and central GABA receptor expression in mice via ingestion of Lactobacillus strain through the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 16050–16055. https://doi.org/10.1073/pnas.1102999108

12. Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., & Cryan, J. F. (2011). Regulation of emotional behavior and central GABA receptor expression in mice via ingestion of Lactobacillus strain through the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 16050–16055. https://doi.org/10.1073/pnas.1102999108

13. Cryan, J. F., & Dinan, T. G. (2012). The impact of gut microbiota on brain and behavior. Nature Reviews Neuroscience, 13(10), 701-712. https://doi.org/10.1038/nrn3346

14. Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behavior. Nature Reviews Neuroscience, 13(10), 701–712. https://doi.org/10.1038/nrn3346

15. Cryan, J. F., & Dinan, T. G. (2012). Review on the impact of gut microbiota on brain and behavior. Gastroenterology, 142(5), 1107-1117. https://doi.org/10.1053/j.gastro.2012.01.027

16. Cussotto, S., Sandhu, K. V., Dinan, T. G., & Cryan, J. F. (2018). The neuroendocrinology of the microbiota-gut-brain axis: A behavioral perspective. Psychoneuroendocrinology, 100, 118-130. https://doi.org/10.1016/j.psyneuen.2018.10.009

17. de Theije, C. G. M., B. M. Z. Sharia, K. W., B. . D. G. M., & C.A. Morrison (2011). Pathways underlying the gut-to-brain connection in autism spectrum disorders. European Journal of Pharmacology, 668(1-2), 253-261. https://doi.org/10.1016/j.ejphar.2011.07.054

18. Desbonnet, L., Garrett, L., Clarke, G., et al. (2008). Assessment of potential antidepressant properties of Bifidobacterium infantis in rats. Journal of Psychiatric Research, 43(2), 165–174. https://doi.org/10.1016/j.jpsychires.2008.04.003

19. Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. Psychiatry Research, 249, 222–226. https://doi.org/10.1016/j.psychres.2016.05.041

20. Dinan, T. G., Stanton, C., & Cryan, J. F. (2013). Psychobiotics as a novel class of psychotropic agents influencing brain function via gut microbiota. Journal of Psychiatric Research, 47(1), 1–13. https://doi.org/10.1016/j.jpsychires.2012.11.001

21. D'Mello, C., Le, T. H., & Swain, M. G. (2015). Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain. Journal of Neuroinflammation, 12, 62. https://doi.org/10.1186/s12974-015-0072-4

22. Evrensel, A., & Ceylan, M. E. (2015). The gut-brain axis as a missing link in depression. Current Psychopharmacology, 4(2), 137–145. https://doi.org/10.2174/2211556004666150417115330

23. Finegold, S. M. (2011). "Intestinal bacterial flora in autism." Anaerobe, 17(6), 250-252. https://doi.org/10.1016/j.anaerobe.2011.08.008

24. Foster, J. A., & McVey Neufeld, K. A. (2013). The gut-brain axis: How the microbiome influences anxiety and depression. Trends in Neurosciences, 36(5), 305–312. https://doi.org/10.1016/j.tins.2013.01.005

25. Gareau, M. G., Wine, E., Rodrigues, D. M., Cho, J. H., Whary, M. T., Philpott, D. J., & Sherman, P. M. (2011). "Bacterial infection causes stress-induced memory dysfunction in mice." Gut, 60(3), 307-318. https://doi.org/10.1136/gut.2010.233926

26. Hsiao, E. Y., et al. (2013). "Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders." Cell, 155(7), 1451-1463. https://doi.org/10.1016/j.cell.2013.11.024

27. Huang, R., Wang, K., & Hu, J. (2016). Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Journal of Affective Disorders, 202, 212–219. https://doi.org/10.1016/j.jad.2016.05.028

28. Jiang, H., Ling, Z., Zhang, Y., et al. (2015). Altered fecal microbiota composition in patients with major depressive disorder. Brain, Behavior, and Immunity, 48, 186–194. https://doi.org/10.1016/j.bbi.2015.03.016

29. Kaluzna-Czaplinska, J., & Blaszczyk, S. (2012). "Arabinitol levels in autistic children after probiotic therapy." Microorganisms, 4(1), 55-61. https://doi.org/10.1007/s11626-012-0187-x

30. Kang, D. W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., & Khoruts, A. (2019). Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microorganisms, 7(1), 1. https://doi.org/10.3390/microorganisms7010001

31. Kato-Kataoka, A., Nishida, K., Takada, M., Kawai, M., Maeda, N., ... & Hoshi, N. (2016). Fermented milk containing Lactobacillus casei strain Shirota reduces psychological distress in medical students: A randomized controlled trial. Psychopharmacology, 233(8), 1497–1506. https://doi.org/10.1007/s00213-016-4293-4

32. Kelly, J. R., Allen, A. P., Temko, A., et al. (2017). Lactobacillus rhamnosus (JB-1) and its effects on stress and cognitive performance in healthy subjects: A randomized controlled trial. Neurobiology of Stress, 7, 123–131. https://doi.org/10.1016/j.ynstr.2017.05.003

33. Kelly, J. R., Borre, Y., C OB, M. L., & Dinan, T. G. (2015). Transferring the microbiome to treat stress-related psychiatric disorders: A gut-brain axis approach. Brain, Behavior, and Immunity, 48, 88–95. https://doi.org/10.1016/j.bbi.2015.03.016

34. Kelly, J. R., Borre, Y., O'Brien, C., et al. (2016). Depression-associated gut microbiota induces neurobehavioral changes in rats. Journal of Neuroscience, 36(3), 982–991. https://doi.org/10.1523/JNEUROSCI.3015-15.2016

35. Kim, S., Kwon, S. H., Kam, T. I., Panicker, N., Karuppagounder, S. S., Lee, S., ... & Dawson, V. L. (2019). "Transneuronal propagation of pathologic α-synuclein from the gut to the brain in Parkinson's disease." Nature Neuroscience, 22(6), 1003-1011. https://doi.org/10.1038/s41593-019-0396-5

36. Kouchaki, E., Tamtaji, O. R., Salami, M., Bahmani, F., Daneshvar, K., ... & Asemi, Z. (2017). "Clinical and metabolic responses to probiotic administration in patients with multiple sclerosis." Journal of Clinical Neuroscience, 44, 85-91. https://doi.org/10.1016/j.jocn.2017.07.013

37. Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D., & Gostner, J. M. (2015). Explorative intervention study on probiotic supplementation in patients with Alzheimer's dementia. Journal of Alzheimer's Disease, 48(3), 579–588. https://doi.org/10.3233/JAD-150938

38. Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D., & Gostner, J. M. (2018). Probiotic supplementation in patients with Alzheimer's dementia: An exploratory intervention study. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 4, 60-64. https://doi.org/10.1016/j.trci.2017.11.002

39. Li, Q., Zhao, L., Wang, J., Wang, Z., Li, L., & Li, J. (2017). Gut microbiota's role in autism spectrum disorders. Microbial Ecology in Health and Disease, 28(1), 1325878. https://doi.org/10.1080/16512235.2017.1325878

40. Liang, S., Wu, X., Wang, T., Wei, X., Xie, Z., & Zhou, Y. (2015). The administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical abnormalities caused by chronic restraint stress in animals. Neurochemical Research, 40(3), 544-553. https://doi.org/10.1007/s11064-015-1607-3

41. Liu, R. T., Walsh, R. F., & Sheehan, A. E. (2019). Systematic review and meta-analysis of prebiotics and probiotics for depression and anxiety, summarizing controlled clinical trials. Journal of Psychiatric Research, 113, 48–58. https://doi.org/10.1016/j.jpsychires.2019.03.018

42. Liu, X., Wang, L., Zhang, J., Zhao, J., Wu, Y., & Liu, Z. (2015). Modulation of the gut microbiota-brain axis by probiotics, prebiotics, and diet. Neuropharmacology, 91, 111-118. https://doi.org/10.1016/j.neuropharm.2014.11.010

43. Maes, M., Kubera, M., & Leunis, J. C. (2008). The gut-brain barrier in major depression: Linking intestinal mucosal dysfunction to the inflammatory pathophysiology. Psychoneuroendocrinology, 33(1), 87–107. https://doi.org/10.1016/j.psyneuen.2007.10.001

44. Mahmoudi, M., Zamani, M., Tavakoli, N., Vakili, S., & Taghizadeh, M. (2019). Probiotic bacteria and Alzheimer's disease: A comprehensive review. Journal of Clinical Neuroscience, 68, 9-18. https://doi.org/10.1016/j.jocn.2019.07.039

45. Mayer, E. A., Knight, R., Mazmanian, S. K., & Cryan, J. F. (2014). The paradigm shift in neuroscience: Gut

microbes and the brain. Neuron, 83(6), 1303-1316. https://doi.org/10.1016/j.neuron.2014.08.018

46. Messaoudi, M., Lalonde, R., Violle, N., Javelot, H., Desor, D., Cazaubiel, M., & Bisson, J.-F. (2011). Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Psychopharmacology, 214(2), 299–307. https://doi.org/10.1007/s00213-010-2209-4
47. Messaoudi, M., Violle, N., Bisson, J. F., Desor, D., Javelot, H., & Rougeot, C. (2011). Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Journal of Clinical Psychopharmacology, 31(5), 513–519. https://doi.org/10.1097/JCP.0b013e31822d20a2
48. Mohajeri, M. H., La Fata, G., Steinert, R. E., & Weber, P. (2018). The relationship between the gut microbiome and brain function. Nutrients, 10(11), 1344. https://doi.org/10.3390/nu10111344
49. Mohammadi, A. A., Jazayeri, S., Khosravi-Darani, K., et al. (2016). Effects of probiotics on mental health and hypothalamic-pituitary-adrenal axis in a randomized, double-blind, placebo-controlled trial with petrochemical workers. Journal of Affective Disorders, 202, 92–98. https://doi.org/10.1016/j.jad.2016.04.015
50. Morshedi, M., Hasheminejad, N., & Fayazi, S. (2021). The effects of probiotics on the severity of Alzheimer's disease: A systematic review. Brain and Behavior, 11(4), e02007. https://doi.org/10.1002/brb3.2007
51. Ng, Q. X., Peters, C., Ho, C. Y., Lim, D. Y., & Yeo, W. S. (2018). Meta-analysis evaluating the use of probiotics to alleviate depressive symptoms. Journal of Affective Disorders, 228, 13–19. https://doi.org/10.1016/j.jad.2017.12.086
52. Ochoa-Reparaz, J., Mielcarz, D. W., Wang, Y., Begum-Haque, S., Dasgupta, S., Kasper, E. J., & Kasper, L. H. (2010). A polysaccharide from Bacteroides fragilis protects against central nervous system demyelinating disease. The Journal of Clinical Investigation, 120(8), 2736-2747. https://doi.org/10.1172/JCI43172
53. O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015). Serotonin, tryptophan metabolism, and the brain-gut-microbiome axis. Gut Microbes, 6(3), 217–226. https://doi.org/10.1080/19490976.2015.1038667
54. Pärtty, A., Kalliomäki, M., Wilska, M., Salminen, S., & Isolauri, E. (2015). Early probiotic intervention and its possible link to reducing neuropsychiatric disorders later in childhood: A randomized trial. Pediatrics, 136(5), e1141-e1147. https://doi.org/10.1542/peds.2015-1570
55. Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Veloso, F., Surette, M. G., & Collins, S. M. (2017). Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity in patients with irritable bowel syndrome. Gastroenterology, 153(2), 317–324. https://doi.org/10.1053/j.gastro.2017.04.058
56. Rieder, R., Wisniewski, P. J., Alderman, B. L., & Campbell, S. C. (2017). Microbes and mental health: A review. Brain, Behavior, and Immunity, 66, 9–17. https://doi.org/10.1016/j.bbi.2017.07.016
57. Romijn, A. R., & Rucklidge, J. J. (2015). Systematic review supporting the theory of psychobiotics, discussing evidence from various studies. Neuropsychopharmacology, 40(2), 190–201. https://doi.org/10.1038/npp.2014.176
58. Romijn, A. R., van der Does, W., Rijkers, G., Kok, J., de Roos, N., & de Lange, M. (2017). Efficacy of Lactobacillus helveticus and Bifidobacterium longum in alleviating symptoms of depression: A double-blind, placebo-controlled trial. Journal of Psychiatric Research, 92, 30-35. https://doi.org/10.1016/j.jpsychires.2017.05.010
59. Romijn, A. R., Rucklidge, J. J., Kuijer, R. G., & Frampton, C. (2017). Double-blind, randomized, placebo-controlled trial of Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 in the treatment of symptoms of depression in adults. Journal of Affective Disorders, 218, 143–150. https://doi.org/10.1016/j.jad.2017.05.021
60. Sampson, T. R., & Mazmanian, S. K. (2015). "Microbiota control brain development, function, and behavior." Cell, 167(4), 909-921. https://doi.org/10.1016/j.cell.2016.10.047
61. Sandler, R. H., Finegold, S. M., Bolte, E. R., Buchanan, C. P., & Lappalainen, J. (2000). Short-term benefit from oral vancomycin treatment of regressive-onset autism. Journal of Child Neurology, 15(7), 429–435. https://doi.org/10.1177/088307380001500702
62. Santocchi, E., Fiori, F., Billeci, L., Narzisi, A., & Calderoni, S. (2016). Probiotics in Autism Spectrum Disorders (ASD): A randomized controlled trial examining clinical, biochemical, and neurophysiological effects. European Child & Adolescent Psychiatry, 25(6), 731-741. https://doi.org/10.1007/s00787-016-0869-x
63. Sarkar, A., Lehto, S. M., Harty, S., & Dunbar, R. I. M. (2016). Psychobiotics and bacteria-gut-brain signals. Journal of Physiology, 594(19), 457–474. https://doi.org/10.1113/JP271529
64. Schmidt, C. (2015). "Mental health and gut microbiota." Microbial Ecology in Health and Disease, 26, 1-3. https://doi.org/10.3402/mehd.v26.27652
65. Schmidt, K., Cowen, P. J., Harmer, C. J., Tzortzis, G., Errington, S., & Burnet, P. W. (2015). Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology, 232(10), 1793–1801. https://doi.org/10.1007/s00213-015-3891-0
66. Selhub, E. M., Logan, A. C., & Bested, A. C. (2014). Fermented foods, microbiota, and mental health. Journal of Physiological Anthropology, 33(1), 1–10. https://doi.org/10.1186/s40101-014-0013-3

67. Shaaban, S. Y., El-Baz, F. A., Khalil, R. R., & Kassem, H. A. (2018). Probiotics for improving symptoms in children with Autism Spectrum Disorder: A prospective, open-label study. Journal of Autism and Developmental Disorders, 48(5), 1494-1503. https://doi.org/10.1007/s10803-017-3356-0
68. Slykerman, R. F., Stanley, T. V., Mitchell, E. A., Tannock, G. W., & Jones, R. B. (2017). The effect of Lactobacillus rhamnosus HN001 during pregnancy on postpartum symptoms of depression and anxiety: A randomized, double-blind, placebo-controlled trial. Psychiatry Research, 247, 127-133. https://doi.org/10.1016/j.psychres.2016.11.045
69. Son, J. S., Kim, H. S., Kim, H. K., Kim, K. H., & Lee, D. S. (2015). Fecal microbiota comparison in children with ASD and neurotypical siblings. PLOS ONE, 10(3), e0139056. https://doi.org/10.1371/journal.pone.0139056
70. Steenbergen, L., Sellaro, R., van Hemert, S., Bosch, J. A., & Colzato, L. S. (2015). Testing multispecies probiotics on cognitive reactivity to sad mood: A randomized controlled trial. Psychopharmacology, 232(9), 1795–1804. https://doi.org/10.1007/s00213-015-3984-7
71. Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., & Koga, Y. (2004). Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. Journal of Physiology, 558(1), 263-275. https://doi.org/10.1113/jphysiol.2004.063388
72. Wall, G. C., Bryant, G. A., Hutton, R. M., & Smith, S. R. (2018). Probiotics for managing inflammatory bowel disease: A review. Journal of Clinical Gastroenterology, 52(2), 98–104. https://doi.org/10.1097/MCG.0000000000000863
73. Wall, R., Cryan, J. F., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2014). Bacterial neuroactive compounds produced by psychobiotics. Trends in Microbiology, 22(9), 497–505. https://doi.org/10.1016/j.tim.2014.05.003
74. Wallace, C. J. K., & Milev, R. (2017). Effects of probiotics on depressive symptoms in humans: A systematic review. Journal of Affective Disorders, 221, 66–72. https://doi.org/10.1016/j.jad.2017.06.019
75. Wang, Y., & Kasper, L. H. (2014). “The role of the microbiome in central nervous system disorders.” Frontiers in Microbiology, 5, 378. https://doi.org/10.3389/fmicb.2014.00378
76. Westfall, S., Lomis, N., Prakash, S., & Singh, S. P. (2017). “Microbiome, probiotics, and neurodegenerative diseases: Implications for the gut-brain axis.” Journal of Neurochemistry, 141(6), 819-828. https://doi.org/10.1111/jnc.14044
77. Williams, J. B., Pang, E., Delgado, A. M., & Telesford, K. M. (2022). “Implications of dietary interventions for autism and ADHD related to the gut microbiome and neurodevelopmental disorders.” Journal of Autism and Developmental Disorders, 52(9), 4056-4068. https://doi.org/10.1007/s10803-021-05390-1
78. Zhuang, Z. Q., Shen, L. L., Li, W. W., Fu, X., Zeng, F., Gui, L., Wang, Y., Zhang, J. Z., & Yan, Z. Q. (2018). Altered gut microbiota in patients with Alzheimer’s disease. Alzheimer’s & Dementia, 14(3), 308-316. https://doi.org/10.1016/j.jalz.2017.11.016

How to cite this article:

VNR Sri Pranavi, B.Vivekananda Reddy N. Jyothsna Reddy and E. Naga Mallika (2024). Psychobiotics: a promising frontier in mental health. *Int J Recent Sci Res*.15(12), pp.5115-5127.

****